当前位置: 首页 >> 检索结果
201. URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers.
作者: Hyun A Lee.;Kyung-Sang Yu.;Sang-In Park.;Seonghae Yoon.;Makoto Onohara.;Youngjoo Ahn.;Howard Lee.
来源: Rheumatology (Oxford). 2019年58卷11期1976-1984页
URC102, a novel and potent inhibitor of human uric acid transporter 1 (hURAT1), is currently under clinical development to treat patients with gout. We performed a randomized, double-blind, placebo-controlled, phase I study to evaluate the safety, tolerability, pharmacodynamic, and pharmacokinetic profiles of URC102 after single and multiple oral administration in healthy male subjects.
202. Effect of probiotics on gastrointestinal symptoms and immune parameters in systemic sclerosis: a randomized placebo-controlled trial.
作者: Thais Fernandes Marighela.;Maria Izabel Arismendi.;Valdecir Marvulle.;Milena Karina Coló Brunialti.;Reinaldo Salomão.;Cristiane Kayser.
来源: Rheumatology (Oxford). 2019年58卷11期1985-1990页
Changes in the intestinal microbiota have been associated with the pathogenesis of SSc. Probiotics act by modulating the microbiome and the immune response. This study aimed to evaluate the efficacy of probiotics on gastrointestinal (GI) symptoms and immune responses in SSc patients.
203. Is self-assessment by patients of disease activity acceptable over the long term in rheumatoid arthritis? A 3-year follow-up of 771 patients.
作者: Laure Gossec.;Françoise Fayet.;Martin Soubrier.;Frantz Foissac.;Anna Molto.;Pascal Richette.;Catherine Beauvais.;Adeline Ruyssen-Witrand.;Aleth Perdriger.;Isabelle Chary-Valckenaere.;Gaël Mouterde.;Emmanuelle Dernis.;Liana Euller-Ziegler.;René-Marc Flipo.;Mélanie Gilson.;Nathalie Balandraud.;Xavier Mariette.;Sophie Pouplin.;Thierry Marhadour.;Thierry Schaeverbeke.;Christelle Sordet.;Maxime Dougados.
来源: Rheumatology (Oxford). 2019年58卷8期1498-1499页 204. Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis.
作者: Sabine Adler.;Stephan Reichenbach.;Andrea Gloor.;Daniel Yerly.;Jennifer L Cullmann.;Peter M Villiger.
来源: Rheumatology (Oxford). 2019年58卷9期1639-1643页
It is currently unknown how long GCA should be treated with tocilizumab. In the first randomized controlled trial, the biologic agent was stopped after 52 weeks. We therefore studied what proportion of patients relapsed, when relapses occurred and whether factors might predict relapse after tocilizumab treatment discontinuation.
205. Added value of biomarkers compared with clinical parameters for the prediction of radiographic spinal progression in axial spondyloarthritis.
作者: Judith Rademacher.;Lorraine Madeline Tietz.;Lien Le.;Agnes Hartl.;Kay-Geert A Hermann.;Joachim Sieper.;Ulrich Mansmann.;Martin Rudwaleit.;Denis Poddubnyy.
来源: Rheumatology (Oxford). 2019年58卷9期1556-1564页
The objective of this study was to examine whether adding biomarkers to routine clinical parameters improves prediction of radiographic spinal progression in axial spondyloarthritis.
206. Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity.
作者: Robert Landewé.;Christopher T Ritchlin.;Daniel Aletaha.;Ying Zhang.;Fabiana Ganz.;Maja Hojnik.;Laura C Coates.
来源: Rheumatology (Oxford). 2019年58卷6期1025-1033页
To evaluate the relationship between radiographic progression and disease activity in subjects with PsA treated with adalimumab (ADA) or placebo (PBO) and the impact of concomitant MTX.
207. Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study.
作者: Naoki Ishiguro.;Yoshiya Tanaka.;Hisashi Yamanaka.;Toshiyuki Yoneda.;Takeshi Ohira.;Naoki Okubo.;Harry K Genant.;Désirée van der Heijde.;Tsutomu Takeuchi.
来源: Rheumatology (Oxford). 2019年58卷6期997-1005页
To evaluate the efficacy of denosumab for progressive bone erosion in risk factor subgroups of Japanese RA patients.
208. Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis.
作者: Paul Emery.;Juan Rondon.;Janie Parrino.;Yong Lin.;Claudia Pena-Rossi.;Hubert van Hoogstraten.;Neil M H Graham.;Nancy Liu.;Anne Paccaly.;Richard Wu.;Alberto Spindler.
来源: Rheumatology (Oxford). 2019年58卷5期849-858页
Safety and efficacy of mAbs blocking the IL-6 receptor have been established in RA. This is the first analysis examining safety and tolerability of sarilumab and tocilizumab administered as single or multiple doses in patients with RA within the same study.
209. Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study.
作者: Jürgen Braun.;Xenofon Baraliakos.;Atul Deodhar.;Denis Poddubnyy.;Paul Emery.;Eumorphia M Delicha.;Zsolt Talloczy.;Brian Porter.
来源: Rheumatology (Oxford). 2019年58卷5期859-868页
To evaluate the effect of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, on efficacy, imaging outcomes, and safety through 4 years (208 weeks) in patients with ankylosing spondylitis.
210. Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis: unpredictable, but predictive of renal outcome.
作者: Maria A C Wester Trejo.;Oliver Floßmann.;Kerstin W Westman.;Peter Höglund.;E Christiaan Hagen.;Michael Walsh.;Jan A Bruijn.;David R W Jayne.;Ingeborg M Bajema.;Annelies E Berden.
来源: Rheumatology (Oxford). 2019年58卷1期103-109页
To determine predictors of renal relapse and end-stage renal failure (ESRF) in patients with ANCA-associated vasculitis.
211. Exposure-response analyses demonstrate no evidence of interleukin 17A contribution to efficacy of ABT-122 in rheumatoid or psoriatic arthritis.
作者: Amit Khatri.;Ben Klünder.;Paul M Peloso.;Ahmed A Othman.
来源: Rheumatology (Oxford). 2019年58卷2期352-360页
ABT-122 is a dual-variable-domain immunoglobulin that neutralizes both TNF-α and IL-17A. The objective of this work was to characterize exposure-response relationships for ABT-122 relative to adalimumab (TNF-α inhibitor) using ABT-122 phase 2 trials in patients with RA or PsA.
212. Triamcinolone acetonide extended-release in patients with osteoarthritis and type 2 diabetes: a randomized, phase 2 study.
作者: Steven J Russell.;Robert Sala.;Philip G Conaghan.;George Habib.;Quang Vo.;Rickey Manning.;Alan Kivitz.;Yvonne Davis.;Joelle Lufkin.;James R Johnson.;Scott Kelley.;Neil Bodick.
来源: Rheumatology (Oxford). 2018年57卷12期2235-2241页
Approximately 30% of patients with type 2 diabetes mellitus have knee osteoarthritis. IA corticosteroids used to manage osteoarthritis pain can elevate blood glucose in these patients. We compared blood glucose levels following intra-articular injection of triamcinolone acetonide extended-release (TA-ER), an extended-release, microsphere-based triamcinolone acetonide formulation, vs standard triamcinolone acetonide crystalline suspension (TAcs) in patients with knee osteoarthritis and comorbid type 2 diabetes.
213. Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study.
作者: Yoshiya Tanaka.;Naonobu Sugiyama.;Shigeyuki Toyoizumi.;Tatjana Lukic.;Manisha Lamba.;Richard Zhang.;Connie Chen.;Thomas Stock.;Hernan Valdez.;Christopher Mojcik.;Haiyun Fan.;Chenhui Deng.;Hirotoshi Yuasa.
来源: Rheumatology (Oxford). 2019年58卷1期70-79页
Tofacitinib is an oral Janus kinase inhibitor for treatment of RA. We compared tofacitinib modified-release (MR) 11 mg once daily (QD) with tofacitinib immediate-release (IR) 5 mg twice daily (BID) in Japanese patients with RA and inadequate response to MTX.
214. Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial.
作者: Fei Yunyun.;Peng Yu.;Zhang Panpan.;Zhang Xia.;Peng Linyi.;Zhou Jiaxin.;Zhang Li.;Zhang Shangzhu.;Liu Jinjing.;Wu Di.;Lai Yamin.;Liu Xiaowei.;Xue Huadan.;Zhang Xuan.;Zeng Xiaofeng.;Zhang Fengchun.;Zhao Yan.;Zhang Wen.
来源: Rheumatology (Oxford). 2019年58卷1期52-60页
This randomized, controlled clinical trial aims to compare the efficacy and safety of glucocorticoid combined with MMF and glucocorticoid monotherapy for patients with IgG4-related disease.
215. Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomised controlled trial.
作者: Lisa K Stamp.;Peter T Chapman.;Murray Barclay.;Anne Horne.;Christopher Frampton.;Paul Tan.;Jill Drake.;Nicola Dalbeth.
来源: Rheumatology (Oxford). 2018年57卷12期2183-2189页
To determine factors that predict inadequate serum urate (SU) lowering response in a randomized controlled trial of allopurinol dose escalation (DE) in gout.
216. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial.
作者: Geetabali Sircar.;Rudra Prosad Goswami.;Dipankar Sircar.;Alakendu Ghosh.;Parasar Ghosh.
来源: Rheumatology (Oxford). 2018年57卷12期2106-2113页
SSc is characterized by fibrotic changes in the skin and lung, and the mainstay of treatment has been CYC. B cell involvement suggests that rituximab (RTX) may also be of therapeutic benefit. The aim of the study was to compare the efficacy and safety of RTX compared with CYC in retarding the progression of interstitial lung disease and skin manifestations of primary SSc.
217. Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2.
作者: Mark C Genovese.;Benard Combe.;Joel M Kremer.;Tsen-Fang Tsai.;Frank Behrens.;David H Adams.;Chin Lee.;Lisa Kerr.;Peter Nash.
来源: Rheumatology (Oxford). 2018年57卷11期2001-2011页
To assess the long-term safety and efficacy of ixekizumab, an IL-17A antagonist, in patients with active PsA.
218. Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis.
作者: Mark C Genovese.;Michael E Weinblatt.;Philip J Mease.;Jacob A Aelion.;Paul M Peloso.;Kun Chen.;Yihan Li.;John Liu.;Ahmed A Othman.;Amit Khatri.;Heikki T Mansikka.;Piotr Leszczynski.
来源: Rheumatology (Oxford). 2018年57卷11期1972-1981页
To evaluate the safety and maintenance of efficacy with ABT-122, a bi-specific monoclonal antibody targeting TNF and IL-17A, in patients with RA or PsA in open-label, 24-week extensions [open-label extensions (OLEs)] of 12-week, randomized, double-blind studies.
219. Barriers to treatment adjustment within a treat to target strategy in rheumatoid arthritis: a secondary analysis of the TRACTION trial.
作者: Agnes Zak.;Cassandra Corrigan.;Zhi Yu.;Asaf Bitton.;Liana Fraenkel.;Leslie Harrold.;Josef S Smolen.;Daniel H Solomon.
来源: Rheumatology (Oxford). 2018年57卷11期1933-1937页
Adherence to a treat to target (TTT) strategy is a recommended paradigm for RA; however, research shows there are many barriers to implementation. We conducted a trial to improve TTT implementation, and herein examine barriers to treatment adjustment within TTT among patient visits not in agreement with the TTT paradigm.
220. Immuno-monitoring reveals an extended subclinical disease activity in tocilizumab-treated giant cell arteritis.
作者: Andrea D Gloor.;Daniel Yerly.;Sabine Adler.;Stephan Reichenbach.;Stefan Kuchen.;Michael Seitz.;Peter M Villiger.
来源: Rheumatology (Oxford). 2018年57卷10期1795-1801页
Tocilizumab is effective in inducing and maintaining remission of GCA. Despite clinical and serological control of disease, magnetic resonance angiography may show persistence of inflammatory signals of unknown significance in arterial walls. Thus, there is an unmet need for tools to detect subclinical disease activity.
|